Transmucosal Fentanyl Products Become First Plug-and-Play REMS
This article was originally published in RPM Report
Executive Summary
When it comes to attempts to control misuse of fast-acting opioids, FDA’s intentions have backfired in the past. Success could point to a likely process for future class-wide REMS.